# Common questions about a sore joint *Joint Care Questions, Answered — Stem Cell Clinic Phoenix* > Does stem cell therapy work, what can it cost, and when is care needed? This stem cell clinic Phoenix FAQ gives straight answers. Phoenix errands can mean long walks across hot parking lots. A joint may feel calm at home, then ache after that distance. The answers below cover relief, office care, cost, and warning signs. Read the answer tied to today's concern first. ## Sources 1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nat Med*, 2023. DOI: 10.1038/s41591-023-02632-w. 2. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample. Cao M, et al. — [Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/40055739/). *Stem Cell Res Ther*, 2025. DOI: 10.1186/s13287-025-04252-2. 3. In a prospective randomized trial of 90 patients with Kellgren-Lawrence grade 1-3 knee osteoarthritis, bone marrow aspirate concentrate produced outcomes equivalent to - not better than - leukocyte-rich platelet-rich plasma through 24 months. Anz AW, et al. — [Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial](https://pubmed.ncbi.nlm.nih.gov/35289231/). *Am J Sports Med*, 2022. DOI: 10.1177/03635465211072554. 4. A phase III double-blind placebo-controlled trial in 261 patients with Kellgren-Lawrence grade 3 knee osteoarthritis tested a single injection of autologous culture-expanded adipose-derived mesenchymal stem cells - a product that cannot legally be sold outside a clinical trial in the United States because culture expansion is more than minimal manipulation. Kim KI, et al. — [Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial](https://pubmed.ncbi.nlm.nih.gov/37345256/). *Am J Sports Med*, 2023. DOI: 10.1177/03635465231179223. 5. A phase 3 placebo-controlled trial of 146 patients using allogeneic bone marrow-derived MSCs (25 million cells) plus hyaluronic acid reported significant WOMAC improvement versus placebo at 6 and 12 months, with a roughly 24 percent relative change - one of the more favourable trials, and it used a culture-expanded product administered with hyaluronic acid rather than a same-day clinic preparation. Gupta PK, et al. — [Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study](https://pubmed.ncbi.nlm.nih.gov/37366164/). *Am J Sports Med*, 2023. DOI: 10.1177/03635465231180323. 6. A meta-analysis of 14 placebo cohorts across 13 Level I trials in 1,076 knee osteoarthritis patients found that intra-articular saline - the placebo - produced pain and function improvements exceeding the minimal clinically important difference at 3 and 6 months. Saltzman BM, et al. — [The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies](https://pubmed.ncbi.nlm.nih.gov/28027657/). *Am J Sports Med*, 2017. DOI: 10.1177/0363546516680607. 7. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable. Previtali D, et al. — [Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression](https://pubmed.ncbi.nlm.nih.gov/41031623/). *EFORT Open Rev*, 2025. DOI: 10.1530/EOR-2025-0022. 8. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added. Bannuru RR, et al. — [OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis](https://pubmed.ncbi.nlm.nih.gov/31278997/). *Osteoarthritis Cartilage*, 2019. DOI: 10.1016/j.joca.2019.06.011. 9. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *null*, 2020. 10. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use. US Code of Federal Regulations, Title 21 — [21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10). *null*, 2004. ## Do regenerative treatments work for every sore joint? Regenerative treatments are non-surgical office procedures using your blood or marrow as the starting point. The clinic takes one from your body, prepares it, and uses a needle to put it in the aching joint. No procedure works for every person or joint. The cause, amount of wear, and your health can't be left out. ## How long can relief last? Relief has no fixed length and may not come at all. Ask the office for exact dates when it will check you. At each check, notice whether the same daily task remains easier. If soreness returns, ask whether exercise, medicine, another opinion, or surgery advice comes next. ## Does stem cell therapy for knees have a set success rate? No honest single rate applies to every knee. One office may offer marrow liquid drawn from the pelvis and spun that day. A study may instead use cells grown in a lab over time. Results from one procedure don't tell you what the other will do. Ask which daily task will be checked after the exact procedure offered. ## How is stem cell therapy cost figured for joint care? The total may include the exam, blood or marrow preparation, the office procedure, and later checks. Ask for a dated written price before agreeing. Your health plan may cover an exam, X-ray, physical therapy, or medicine. Ask it directly about the planned procedure. Financing changes when you pay, but it doesn't improve the result. ## Where is the nearest Phoenix clinic? The Banner Estrella location is at 9305 W. Thomas Rd., Suite 460, Phoenix, AZ 85037. The clinic phone is (602) 837-PAIN. Ask whether someone must drive you home. If walking is hard, ask about the distance from the car to the office. ## When does joint soreness need prompt care? Prompt care is needed when a fever starts and a joint feels hot or looks swollen. After a major injury, seek help if you can't stand safely. A bent-looking joint or sudden weakness also needs fast care. Back pain becomes more urgent if numbness or weakness begins, or you lose bladder or bowel control. ## An exam can help when soreness stays When home care hasn't helped enough, QC Kinetix can review your joint. Care comes from medical providers, meaning the clinicians who check the joint and discuss non-surgical choices. Write down every medicine, take your X-ray report, and note difficult daily tasks. For the west-Phoenix location, use 9305 W. Thomas Rd., Suite 460, Phoenix, AZ 85037, or call (602) 837-PAIN. Book a free consultation: --- Understand the soreness. Know your choices. Plain guidance for a sore Phoenix joint, helpful home care, office visits, and non-surgical choices when aching stays. Plain facts about sore joints and ways to prepare for an office visit. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Banner Estrella, Scottsdale, Peoria, and Chandler locations, and the business can benefit when a reader books. © 2026 Phoenix Trial Ledger. General health education, not medical advice or a diagnosis for your joint.